LT 3002
Alternative Names: LT-3002Latest Information Update: 25 Apr 2024
At a glance
- Originator LTT Bio-Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Chronic obstructive pulmonary disease
Most Recent Events
- 05 Apr 2024 LT 3002 is available for licensing as of 05 Apr 2024. https://www.ltt.co.jp/en/partnership/licensing/licenceout/ (LTT Bio-Pharma website, April 2024)
- 05 Apr 2024 LTT Bio-Pharma has patent protection for LT 3002 (LTT Bio-Pharma Website, April 2024)
- 05 Apr 2024 Preclinical trials in Chronic obstructive pulmonary disease in Japan (unspecified route) prior to April 2024 (LTT Bio-Pharma pipeline, April 2024)